Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Lumos Pharma, Inc. LUMO
$3.39
-$0.02 (-0.73%)
На 18:02, 12 мая 2023
+386.73%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
28697165.00000000
-
week52high
9.56
-
week52low
2.95
-
Revenue
1523000
-
P/E TTM
-1
-
Beta
0.65472200
-
EPS
-4.07000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 20:30
Описание компании
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | 20 июл 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 04 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 21 июл 2021 г. |
| Stifel | Buy | Hold | 11 мар 2021 г. |
| Cantor Fitzgerald | Overweight | 03 дек 2020 г. | |
| Jefferies | Hold | Buy | 15 ноя 2022 г. |
| Jefferies | Hold | Buy | 08 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| McKew John C. | D | 26457 | 439 | 02 февр 2023 г. |
| Hawkins Richard J | A | 35400 | 35400 | 01 февр 2023 г. |
| Hawkins Richard J | D | 752327 | 416 | 01 февр 2023 г. |
| Hawkins Richard J | A | 752743 | 4500 | 01 февр 2023 г. |
| Karpf David B | A | 12000 | 12000 | 01 февр 2023 г. |
| Karpf David B | D | 8294 | 36 | 01 февр 2023 г. |
| Karpf David B | A | 8330 | 1000 | 01 февр 2023 г. |
| Lawley Lori D | A | 12000 | 12000 | 01 февр 2023 г. |
| Lawley Lori D | D | 11505 | 114 | 01 февр 2023 г. |
| Lawley Lori D | A | 11619 | 1000 | 01 февр 2023 г. |
Новостная лента
Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
14 ноя 2022 г. в 09:02
Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
09 авг 2022 г. в 20:36
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Lisa Miller - Senior Director of Investor Relations Richard Hawkins - Chairman and Chief Executive Officer Lori Lawley - Chief Financial Officer John McKew - President and Chief Scientific Officer David Karpf - Chief Medical Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald, L.P Emma Nesson - Piper Sandler & Co. Edward White - H.C. Wainwright & Co, LLC Catherine Novack - Jones Research Leland Gershell - Oppenheimer & Co. Inc. Elemer Piros - ROTH Capital Partners Operator Good afternoon, and welcome to Lumos Pharma's Second Quarter 2022 Results and Clinical Update Conference Call.
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
09 авг 2022 г. в 19:33
Lumos (LUMO) delivered earnings and revenue surprises of 4.08% and 266.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma to Participate in Upcoming Investor Conferences
GlobeNewsWire
16 мая 2022 г. в 16:05
AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences:
Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call Transcript
Seeking Alpha
10 мая 2022 г. в 22:03
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Lisa Miller - Senior Director, IR Richard Hawkins - CEO & Chairman John McKew - Chief Scientific Officer & President David Karpf - Chief Medical Officer Lori Lawley - CFO & Principal Accounting Officer Conference Call Participants Avraham Novick - Cantor Fitzgerald & Co. Yasmeen Rahimi - Piper Sandler & Co. Catherine Novack - JonesTrading Institutional Services Edward White - H.C. Wainwright & Co. Operator Good afternoon, and welcome to Lumos Pharma's First Quarter 2022 Results & Clinical Update Conference Call.